Journal profile · Chemistry, Analytical
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
ISSN 0362-4803 · eISSN 1099-1344 · John Wiley and Sons Ltd · ENGLAND · Monthly · Founded 1976
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.33; hybrid open access; APC about USD 3,800; median 87 days to acceptance (66 articles, last 24 months); community-reported acceptance: easy; 62 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS is published by John Wiley and Sons Ltd and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Radiopharmaceutical Chemistry and Applications, Chemical Reactions and Isotopes and Medical Imaging Techniques and Applications, together about 37.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
The Journal of Labelled Compounds and Radiopharmaceuticals publishes all aspects of research dealing with labeled compound preparation and applications of these compounds. This includes tracer methods used in medical, pharmacological, biological, biochemical and chemical research in vitro and in vivo. The Journal of Labelled Compounds and Radiopharmaceuticals devotes particular attention to biomedical research, diagnostic and therapeutic applications of radiopharmaceuticals, covering all stages of development from basic metabolic research and technological development to preclinical and clinical studies based on physically and chemically well characterized molecular structures, coordination compounds and nano-particles. JLCR Award for Young Scientists (“Wiley Award”): The Journal of Labelled Compounds and Radiopharmaceuticals sponsors every year four awards for early excellence in radiopharmaceutical research and isotope labeling in close cooperation with the following organisations (these awards are drawn from participant submissions within these meetings and adjudicated by the local organising committee): JLCR Cooperation with Societies: The Journal of Labelled Compounds and Radiopharmaceuticals is the official Journal of the International Isotope Society IIS
From the journal's Aims & Scope
Research area (LetPub): Chemistry, Analytical
Editor-in-chief V DerdauPublisher website
Editorial board by country: 3 in mainland China (about 8%); most named United States 11, United Kingdom 8, Mainland China 3, Switzerland 3, France 2 (39 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Radiopharmaceutical Chemistry and ApplicationsMedicine15.6%
- Chemical Reactions and IsotopesPharmacology, Toxicology and Pharmaceutics14.1%
- Medical Imaging Techniques and ApplicationsMedicine7.8%
- Chemical Synthesis and AnalysisBiochemistry, Genetics and Molecular Biology6.5%
- Synthesis and Biological EvaluationChemistry6.5%
- Fluorine in Organic ChemistryPharmacology, Toxicology and Pharmaceutics6.1%
- Cancer therapeutics and mechanismsBiochemistry, Genetics and Molecular Biology4.5%
- Analytical Chemistry and ChromatographyChemistry3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biochemical Research Methods | Zone 4 |
| Minor | Chemistry, Analytical | Zone 4 |
| Minor | Chemistry, Medicinal | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biochemical Research Methods | Zone 4 |
| Minor | Chemistry, Medicinal | Zone 4 |
| Minor | Chemistry, Analytical | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biochemical Research Methods | Zone 4 |
| Minor | Chemistry, Analytical | Zone 4 |
| Minor | Chemistry, Medicinal | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EI CompendexWeb of ScienceMEDLINEPubMedEmbaseCASCurrent ContentsPublisher website
Other: ProQuest
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.33LetPub ·
- Impact factor (publisher) 2025
- 1.3Publisher website ·
- CiteScore 2026-06
- 1.9LetPub ·
- CiteScore (publisher) 2025
- 1.9Publisher website ·
- SJR 2026-06
- 0.29LetPub ·
- SNIP 2026-06
- 0.39LetPub ·
- h-index
- 41LetPub ·
- h-index
- 67OpenAlex ·
- i10-index
- 1,494OpenAlex ·
- 2-year mean citedness
- 0.6OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 32.23%LetPub ·
Volume
- Articles per year
- 36LetPub ·
- Articles per year (publisher) 2025
- 41Publisher website ·
- Downloads per year (publisher) 2025
- 129,537Publisher website ·
Articles by year OpenAlex count · 8,611 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 37 | 12 | 5 |
| 2025 | 62 | 25 | 34 |
| 2024 | 59 | 34 | 56 |
| 2023 | 77 | 47 | 244 |
| 2022 | 63 | 19 | 140 |
| 2021 | 112 | 18 | 171 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
87 daysMedian, submission to acceptance · P25–P75 56 days – 148 days
- Acceptance to online
- median 16 days (66 articles)
- Submission to online
- median 103 days
- Sample
- 66 articles with submission and acceptance dates (89 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Acceptance rate (publisher) 2025
- 57%Publisher website ·
- Submission to first decision 2025
- 22 daysPublisher website ·
- Submission to acceptance 2025
- 87 daysPublisher website ·
- Acceptance to publication 2025
- 16 daysPublisher website ·
- Peer review
- Single-anonymous peer reviewPublisher website · model-extracted
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,800 / EUR 3,170 / GBP 2,550 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Page charges
- No page charges
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare7 items from the author guidelines
- Abstract
- ≤ 250 words
- Reference style
- AMA
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Required
- Highlights
- Required
- Graphical abstract
- Required
- Cover letter
- Required
Article types accepted7, with length limits
- perspectiveby the Perspective. We would encourage perspectives of around 2000 words, with 1-2 figures. Perspectives are generally invited, butmain text ≤ 2,000 words
- perspectivesJournal of Labelled Compounds and Radiopharmaceuticals publishes Reviews, Research Articles, Protocols, Short Notes, and PerspectivesLength not stated
- protocolThese are short articles reporting on useful tips and applications in a practitioner setting. Application are encouraged from both independent authors and produ…main text ≤ 500 words
- protocolsJournal of Labelled Compounds and Radiopharmaceuticals publishes Reviews, Research Articles, Protocols, Short Notes, and PerspectivesLength not stated
- research articlesJournal of Labelled Compounds and Radiopharmaceuticals publishes Reviews, Research Articles, Protocols, Short Notes, and PerspectivesLength not stated
- reviewsJournal of Labelled Compounds and Radiopharmaceuticals publishes Reviews, Research Articles, Protocols, Short Notes, and PerspectivesLength not stated
- short notesJournal of Labelled Compounds and Radiopharmaceuticals publishes Reviews, Research Articles, Protocols, Short Notes, and PerspectivesLength not stated
Policy excerpts from the journal's websiteConflicts of interest, Data availability, Publication ethics, License & copyright, Preprints
- Conflicts of interest Disclosure Statement
Journal of Labelled Compounds and Radiopharmaceuticals requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise, that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the …
Source ↗Publisher website ·- Data availability Data Sharing and Data Availability
Data sharing expected; authors select a data availability statement per Wiley policy. Model summary
This journal expects data sharing. Review Wiley’s Data Sharing policy where you will be able to see and select the data availability statement that is right for your submission.
Source ↗Publisher website ·- Publication ethics
Ethics approval required for human/animal studies; clinical investigations must follow the Declaration of Helsinki. Model summary
All human and animal studies must be approved by an appropriate ethics committee or review board (depending on local arrangements), and a statement to this effect should be included in the methods section, or the reasons why it was not necessary if this is the case. All clinical investigations must have been conducted according to the principles expressed in the Declaration of Helsinki
Source ↗Publisher website ·- License & copyright Copyright and Permissions
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper. For authors signing the copyright transfer agreement If the OnlineOpen option is not select…
Source ↗Publisher website ·- Preprints Preprint Policy
Preprint policy: preprints accepted; submitted versions may be posted to preprint servers at any time. Model summary
This journal accepts articles previously published on preprint servers. The Journal of Labelled Compounds and Radiopharmaceuticals will consider for review articles previously available as preprints. You may also post the submitted version of a manuscript to a preprint server at any time. You are requested to update any pre-publication versions with a link to the final published article. Please fi…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- John Wiley and Sons Ltd
- Country or region
- ENGLAND
- Language
- Multi-Language
- Frequency
- Monthly
- Founded
- 1976
- ISSN
- 0362-4803
- Electronic ISSN
- 1099-1344
- Society / sponsor
- International Isotope Society
- Latest issue on the website
- Volume 69, Issue 10-11 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
What CAS zone is JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS in?
In the 2025 upgraded edition of the CAS Journal Ranking, JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS is in Zone 4 of Medicine, and in Zone 4 of the minor category Biochemical Research Methods / Chemistry, Analytical / Chemistry, Medicinal. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS?
The latest impact factor listed by LetPub is 1.33; CiteScore 1.9, h-index 67.
How long does peer review take at JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS?
Based on the dates recorded on 66 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 87 days (interquartile range 56–148 days); authors report an average review time of about 1 month; the community-reported acceptance is “Easy”; the journal's website gives an acceptance rate of 57% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS?
According to the journal's author guidelines: Abstract: ≤ 250 words; Reference style: AMA; First submission: Free format: the journal's layout is not required; Suggested reviewers: Required; Highlights: Required; Graphical abstract: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS based?
Of the 39 board members whose country the journal's board page names, 3 (about 8%) are in mainland China; the countries named most often are United States (11), United Kingdom (8) and Mainland China (3). Counted from the institutions listed on the board page; for reference only.
Which databases index JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS?
According to LetPub and DOAJ records, JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS is indexed in SCIE and Scopus. The journal's website also lists EI Compendex, Web of Science, MEDLINE, PubMed, Embase, CAS and Current Contents; that list has not been checked against each database.
Is JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS open access, and what is the APC?
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS is a hybrid journal. For open-access publication: APC about USD 3,800.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .